Back to Top Skip to main content

Defending the Homeland: Turning on lifesaving trials at Madigan Army Medical Center

Image of soldier in front of a laptop Janell Cain, a clinical research coordinator at Madigan with the Infectious Disease Clinical Research Program, records the informed consent forms signed by a patient receiving treatment for COVID-19 in the intensive care unit from Madigan’s Virtual Critical Care Center on April 14. Communicating with the patient and nurses via the video equipment, Cain gains the necessary consent to enroll a patient in a study of remdesivir as a COVID-19 treatment without expending personal protective equipment, or exposing anyone to the patient unnecessarily. The IDCRP is a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. (Lt. Col. (Dr.) Christopher Colombo)

Recommended Content:

Coronavirus

MADIGAN ARMY MEDICAL CENTER, Joint Base Lewis-McChord, Wash. – Madigan Army Medical Center, on Joint Base Lewis-McChord, Wash., has been a hotbed for biomedical research for years, highlighted by patented innovations and award winning presentations at national and international scientific meetings.

In response to the COVID-19 global pandemic, Madigan is currently supporting nine research protocols designed to address gaps in knowledge including clinical characteristics of the COVID-19 illness, the impact of nutrition on COVID-19 risk, and the clinical value of convalescent plasma, in which a patient with severe disease is given plasma from someone who has recovered from COVID-19 and therefore has antibodies to it in their blood, to name a few.

Possibly the most notable clinical trial for COVID-19 treatment involves remdesivir, an investigational, broad-spectrum antiviral drug that has shown some promise, in animal trials, in both Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by other coronaviruses.

The trial is sponsored by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, and is the first clinical trial in the U.S. to evaluate an experimental treatment for COVID-19.

When the trial began in February, Dr. Anthony Fauci, the director of NIAID and a member of the U.S. Coronavirus Task Force said, “We urgently need a safe and effective treatment for COVID-19. Although remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes. A randomized, placebo-controlled trial is the gold standard for determining if an experimental treatment can benefit patients.”

Madigan is one of 68 international trial sites among 47 in the U.S. and 21 in Europe and Asia. The first enrollee was at the University of Nebraska Medical Center/Nebraska Medicine, in February; he had been on a cruise ship that saw a number of infections.

The initiation of the trial can is described here: https://www.niaid.nih.gov/news-events/nih-clinical-trial-remdesivir-treat-covid-19-begins.

Within two months of initiation, the clinical trial of remdesivir has produced encouraging results.

In a statement issued on April 29, the NIAID reported, “Preliminary results indicate that patients who received remdesivir had a 31 percent faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0 percent for the group receiving remdesivir versus 11.6 percent for the placebo group (p=0.059).”

This trial is managed at Madigan by the Infectious Disease Clinical Research Program, a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. The IDCRP conducts clinical research that focuses on reducing the impact of infectious diseases relevant to the DoD.

For more information about the IDCRP, visit: https://www.idcrp.org/about-us.

The IDCRP has a broad research portfolio, including an ongoing study looking at the efficacy of different formulations of the flu vaccine. When COVID-19 emerged, the IDCRP pivoted to get this research up and running in a very short period of time. As an established IDCRP site, Madigan was identified as one of the military treatment facilities eligible for participation in the NIAID trial.

“Because they are so active and such a squared-away group, they were able to help get this trial off the ground,” said Lt. Col. (Dr.) Christopher Colombo, principal investigator for the COVID-19 trial and the director of Virtual Health and Telecritical Care at Madigan.

Madigan has strong and adaptive biomedical research capabilities that are facilitated by its Department of Clinical Investigation.

“The Department of Clinical Investigation, Dr. Rick Burney (DCI’s chief) and Dr. (Silvija) Salai (the human subject protection administrator), have been fantastic in supporting and expediting this and balancing making sure that everything is still done dress-right-dress according to regulatory, safety and scientific integrity filings, but it is going quite a bit faster than usual, because of the situation that we're in,” noted Lt. Col. Colombo.

Madigan is one of five DoD sites that has enrolled patients in the study so far and is already ramping up for its next phase. Investigators stress that these are early days of evaluation for this trial. Given the high transmissibility and global spread of this virus, research has moved quickly.

“It's a placebo controlled trial, so the patients are randomized. We don't know who's getting what. They either get placebo or remdesivir,” Lt. Col. Colombo said.

NIH requirements for inclusion in the trial comprise the need for hospitalization for documented COVID-19 infection and either an abnormal chest x-ray or the requirement for supplemental oxygen or mechanical ventilation. Trial participation is limited to adults.

Participants in the treatment group get 200 milligrams (mg) of remdesivir injected on the first day they are in the study and 100 mg each day of their hospitalization, up to 10 days total. Those in the placebo group receive the same amount of what looks like remdesivir but contains only inactive ingredients.

This means the trial is administered to patients currently being treated in the hospital, though some have since improved and gone home. They return to the hospital periodically for monitoring.

Dr. Rhonda Colombo, an infectious diseases physician who works in support of the IDCRP at Madigan, praised the contributions of patients who volunteered to participate in this and other ongoing clinical research trials.

“Without willing and engaged study participants, clinical research is not possible. At Madigan, we are incredibly fortunate to be part of a community that values clinical research. Our research team is humbled by the generosity and commitment of the people who volunteer to participate in our studies,” said Dr. Colombo.

With drug safety and long-term effects always in mind, the team is not yet ready to draw conclusions, but is optimistic about the data so far.

Susan Chambers, the clinical operations manager for the IDCRP at Madigan echoed that appreciation for the high value that Madigan, and the JBLM community place on research, noting that it is the providers and nurses on the inpatient units who directly support research within their care of patients.

“We are incredibly proud to have the opportunity to offer access to cutting-edge research for our Active Duty personnel and DoD beneficiaries. Our success would not be possible without the support of Madigan Commander Col. Thomas Bundt and the committed inpatient clinical care teams at Madigan,” said Chambers.

On Friday, May 1, the U.S. Food and Drug Administration gave remdesivir emergency use authorization to treat COVID-19.

The NIAID expects to share additional data soon, as well as next steps.

“We managed to get meaningful research turned on, very quickly. Other sites in the Department of Defense, are kind of looking at Madigan like you guys are knocking it out of the park, keep going,” said Lt. Col. Colombo. “I think it's something that's cool in terms of how we're responding to COVID in a positive way and making some good come of this.”

Disclaimer: Re-published content may be edited for length and clarity.  Read original post.

You also may be interested in...

Minimize COVID-19 holiday spread with small gatherings, mask wearing

Article
11/25/2020
Soldiers standing in a line, wearing masks

The holiday season is upon us, and so is a drastic rise in coronavirus cases.

Recommended Content:

Coronavirus

NMRTU Everett Hospitalman makes a difference

Article
11/24/2020
Technician wearing a mask, giving a shot to a soldier

For much of 2020, Scott has also done her share and more to help stop the spread of COVID-19.

Recommended Content:

Coronavirus | Public Health

Army conducts commercial aircraft decontamination efficacy test

Article
11/24/2020
Man wearing mask, looking at ceiling of an airplane

Two commercial sprayers and two commercial liquid disinfectants will be tried in different combinations on surfaces in the passenger area to gauge effectiveness.

Recommended Content:

Coronavirus

Navy PA continues to care for COVID-19 caregivers

Article
11/19/2020
Three soldiers, wearing masks, demonstrating a hearing test

As a PAt, Osborn works hand-in-hand with supervising physicians and surgeons.

Recommended Content:

Coronavirus

NICoE & ISC Network maintain TBI care during COVID-19

Article
11/19/2020
Image of United States map with locations noted

The Network leveraged their geographic distribution to help each other quickly adapt to changing times.

Recommended Content:

Coronavirus | Traumatic Brain Injury

San Antonio volunteers sought for Warp Speed vaccine trials

Article
11/18/2020
Woman typing on laptop

DOD sites are open on a voluntary basis to Military Health System beneficiaries.

Recommended Content:

COVID-19 Vaccine Efforts | Coronavirus

Army combat medic earns U.S. citizenship, plans to continue serving

Article
11/18/2020
Two men wearing masks, one in a car, one leaning in the car

The native of Brazil is part of the COVID-19 testing team.

Recommended Content:

Coronavirus

Army doctors provide COVID-19 safety tips for the holiday season

Article
11/17/2020
Soldiers wearing masks, looking at flight information in airport

Celebrating the holidays during a pandemic may bring additional challenges for people this year.

Recommended Content:

Coronavirus | November Toolkit | November Holidays and Observances

Military Health System participating in COVID-19 vaccine trial

Article
11/17/2020
Woman measuring out a vaccine into a needle

How you can help test the vaccine.

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

DHA leaders recognize CCP collection campaign contributors & donors

Article
11/16/2020
Three military personnel in uniform, wearing masks, in front of flags

The ceremony honored those who contributed to exceeding the goal of collecting 10,000 units of COVID-19 convalescent plasma.

Recommended Content:

Coronavirus | Convalescent Plasma Collection Program

NMRTU Everett staff collaborate to ensure Patient Centered Care

Article
11/16/2020
Image of two military personnel wearing masks

NMRTU Everett was commended by the MHS 2020 Advancement towards High Reliability Healthcare Awards Program as a Patient Centeredness Award winner.

Recommended Content:

Combat Support | Public Health | Coronavirus

Holiday Season Guidance to Minimize Spread of the Coronavirus Disease 2019

Publication
11/16/2020

This memorandum provides guidance to help protect individuals within the DoD community from coronavirus disease 2019 (COVID-19) for gatherings and activities during the November to January holiday season.

Recommended Content:

Coronavirus

Naval Medical Forces Pacific’s commander tours NH Twentynine Palms

Article
11/12/2020
Four military personnel in uniform, wearing masks

Weber was briefed on the implementation of MHS GENESIS...and the hospital's response to COVID-19.

Recommended Content:

Combat Support | Health Readiness | Coronavirus | MHS GENESIS

Forging of civil-military anvil against COVID-19 focus at GHSA

Article
11/9/2020
U.S. and Thai soldiers stand together during a medical exercise.

“Defense partnerships around the world are key.”

Recommended Content:

Coronavirus | Global Health Engagement | Health Readiness | Global Health Engagement

Wave PENDLETON sees more MTFs deploy new electronic health record

Article
11/5/2020
Military technician, wearing a mask, in front of a computer screen

Wave PENDLETON is the third major deployment of MHS GENESIS.

Recommended Content:

Public Health | Coronavirus | MHS GENESIS
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 20

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.